122 related articles for article (PubMed ID: 37248927)
41. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
Chen Z; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
[TBL] [Abstract][Full Text] [Related]
42. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
43. [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].
Zemaitis M; Sakalauskas R; Malakauskas K; Muley T; Fischer JR; Lahm H
Medicina (Kaunas); 2005; 41(7):566-76. PubMed ID: 16062024
[TBL] [Abstract][Full Text] [Related]
44. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
Clevers MR; Kastelijn EA; Peters BJM; Kelder H; Schramel FMNH
Anticancer Res; 2021 Feb; 41(2):869-876. PubMed ID: 33517292
[TBL] [Abstract][Full Text] [Related]
46. Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma.
Li Z; Wu W; Pan X; Li F; Zhu Q; He Z; Chen L
Cancer Med; 2022 Jul; 11(14):2855-2864. PubMed ID: 35289087
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
Reinmuth N; Brandt B; Semik M; Kunze WP; Achatzy R; Scheld HH; Broermann P; Berdel WE; Macha HN; Thomas M
Lung Cancer; 2002 Jun; 36(3):265-70. PubMed ID: 12009236
[TBL] [Abstract][Full Text] [Related]
48. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.
Li Q; Jiang M; Han X; Yang Z; Shu W; Ding X
J Cancer Res Ther; 2020; 16(2):222-229. PubMed ID: 32474505
[TBL] [Abstract][Full Text] [Related]
49. Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer.
Shan Y; Yin X; Zhao N; Wang J; Yang S
Minerva Med; 2023 Dec; 114(6):795-801. PubMed ID: 33764713
[TBL] [Abstract][Full Text] [Related]
50. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
51. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
52. [Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer].
Xu C; Liu J; Xing L; Liu S
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):954-61. PubMed ID: 20959068
[TBL] [Abstract][Full Text] [Related]
53. The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer.
Zhao C; Li J; Zhang Y; Han R; Wang Y; Li L; Zhang Y; Zhu M; Zheng J; Du H; Hu C; Zhou C; Yang N; Cai S; He Y
Cancer Med; 2023 Mar; 12(5):5603-5614. PubMed ID: 36341686
[TBL] [Abstract][Full Text] [Related]
54. [Clinical value of serum TPS, CEA, Pro-GRP and CYFRA21-1 in patients with lung cancer].
Wang J; Shi G; Zhang S; Wang Q; Yang X; Li X; Wang H; Zhang H; Song C
Zhongguo Fei Ai Za Zhi; 2010 May; 13(5):500-5. PubMed ID: 20677649
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis.
Chu XY; Hou XB; Song WA; Xue ZQ; Wang B; Zhang LB
Cancer Biol Ther; 2011 Jun; 11(12):995-1000. PubMed ID: 21483235
[TBL] [Abstract][Full Text] [Related]
56. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
57. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
58. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
59. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
